Your browser doesn't support javascript.
loading
Arsenic trioxide suppresses lung adenocarcinoma stem cell stemness by inhibiting m6A modification to promote ferroptosis.
Jin, Wen; Sun, Yu; Wang, Jiaqi; Wang, Yan; Chen, Dan; Fang, Ming; He, Jie; Zhong, Linsheng; Ren, Hao; Zhang, Yuanmei; Yin, Hao; Wu, Shijia; Chen, Ruqin; Yan, Wen.
Afiliação
  • Jin W; Department of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
  • Sun Y; Department of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
  • Wang J; Department of Oncology, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
  • Wang Y; Department of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
  • Chen D; Department of Oncology, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
  • Fang M; Department of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
  • He J; Department of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
  • Zhong L; Department of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
  • Ren H; Department of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
  • Zhang Y; Department of Ultrasound, The First Affiliate Hospital of Guangzhou Medical University Guangzhou 510120, Guangdong, China.
  • Yin H; Department of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
  • Wu S; Department of Cardiac Intensive Care Unit, The Cardiovascular Hospital, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
  • Chen R; Department of Traditional Chinese Medicine, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
  • Yan W; Department of Oncology, The Second People's Hospital of Guangdong Province Guangzhou 510310, Guangdong, China.
Am J Cancer Res ; 14(2): 507-525, 2024.
Article em En | MEDLINE | ID: mdl-38455419
ABSTRACT
Arsenic trioxide (ATO) is well known for its inhibitory effects on cancer progression, including lung adenocarcinoma (LUAD), but the molecular mechanism remains elusive. This study aimed to investigate the roles of ATO in regulating LUAD stem cells (LASCs) and the underlying mechanisms. To induce LASCs, cells cultured in an F12 medium, containing B27, epidermal growth factor, and basic fibroblast growth factor, induced LASCs. LASCs stemness was assessed through tumor sphere formation assay, and percentages of CD133+ cells were detected by flow cytometry. The Cell Counting Kit-8 method was used to assess LASCs viability, while reactive oxygen species (ROS) and iron ion levels were quantitated by fluorescence microscopy and spectrophotometry, respectively, and total m6A levels were measured by dot blot. Additionally, LASCs mitochondrial alterations were analyzed via transmission electron microscopy. Finally, the tumorigenicity of LASCs was assessed using a cancer cell line-based xenograft model. Tumor sphere formation and CD133 expression were used to validate the successful induction of LASCs from A549 and NCI-H1975 cells. ATO significantly inhibited proliferation, reduced ZC3H13 expression and total m6A modification levels, and increased ROS and iron ion content, but repressed sphere formation and CD133 expression in LASCs. ZC3H13 overexpression or ferrostatin-1 treatment abrogated LASCs stemness inhibition caused by ATO treatment, and interference with ZC3H13 inhibited LASCs stemness. Furthermore, the promotion of LASCs ferroptosis by ATO was effectively mitigated by ZC3H13 overexpression, while interference with ZC3H13 further promoted ferroptosis. Moreover, si-ZC3H13 promoted ferroptosis and impaired stemness in LASCs, which ferrostatin-1 abrogated. Finally, ZC3H13 overexpression alleviated the inhibitory effects of ATO on LASCs tumorigenicity. Taken together, ATO treatment substantially impaired the stemness of LUAD stem cells by promoting the ferroptosis program, which was mediated by its ZC3H13 gene expression inhibition to suppress m6A medication.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Cancer Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Cancer Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China